Core Laboratories N.V. financials
Core Laboratories N.V.
Country: NL Reporting currency: USD Latest annual report: 2021-12-31
LEI:
724500MDYY5VBSAF5W50 Financial statements
(USD, as reported — unscaled; 112 line items across 2 annual periods)
| Line item | 2021 | 2020 |
|---|---|---|
| Income statement | ||
| Revenue | $470.3M | $487.3M |
| Cost of sales | $381.3M | $401.7M |
| Gross profit | $89.0M | $85.6M |
| Operating profit (EBIT) | $50.0M | $40.1M |
| Finance costs | $12.0M | $17.6M |
| Profit before tax | $38.1M | $22.6M |
| Income tax expense | $14.2M | $13.0M |
| Profit for the year | $23.9M | $9.2M |
| — attributable to owners | $23.4M | $9.1M |
| — attributable to NCI | $492.0K | $140.0K |
| Total comprehensive income | $21.1M | $8.5M |
| Per share | ||
| Basic EPS | $0.51 | $0.20 |
| Diluted EPS | $0.50 | $0.20 |
| Free cash flow / share | $0.84 | $1.41 |
| Cash flow statement | ||
| Cash generated from operations | $72.5M | $108.3M |
| Net cash from operating activities | $52.9M | $75.3M |
| Income taxes paid | $9.1M | $21.3M |
| Net cash from investing activities | -$10.2M | $7.9M |
| Purchase of PP&E (capex) | $13.5M | $11.9M |
| Purchase of intangibles | $318.0K | $498.0K |
| Net cash from financing activities | -$38.8M | -$80.4M |
| Dividends paid | $1.8M | $12.4M |
| Proceeds from borrowings | $155.0M | $56.0M |
| Repayments of borrowings | $226.0M | $102.0M |
| Lease liability payments | $16.4M | $17.0M |
| Balance sheet | ||
| Total assets | $769.5M | $755.3M |
| Non-current assets | $553.1M | $563.8M |
| Property, plant & equipment | $111.0M | $115.3M |
| Right-of-use assets | $59.3M | $64.1M |
| Intangible assets & goodwill | $267.8M | $268.3M |
| Current assets | $216.4M | $191.6M |
| Inventories | $45.4M | $38.2M |
| Trade & other receivables | $96.8M | $83.2M |
| Cash & equivalents | $17.7M | $13.8M |
| Total equity | $337.4M | $249.4M |
| — attributable to owners | $332.9M | $245.4M |
| Non-controlling interests | $4.6M | $4.1M |
| Non-current liabilities | $336.7M | $411.9M |
| Long-term borrowings | $188.6M | $259.4M |
| Lease liabilities (non-current) | $49.3M | $56.1M |
| Current liabilities | $95.3M | $94.0M |
| Lease liabilities (current) | $12.3M | $11.4M |
| Trade & other payables | $29.7M | $22.5M |
| Deferred tax liabilities | $28.2M | $24.4M |
| Derived metrics | ||
| Free cash flow | $39.4M | $63.4M |
| Operating margin | 10.6% | 8.2% |
| Net margin | 5.1% | 1.9% |
| Return on equity | 7.1% | 3.7% |
| Cash conversion ratio | 2.21× | 8.18× |
| Capex coverage | 3.91× | 6.34× |
| Other reported items | ||
| Adjusted Weighted Average Shares | 0.0M | 0.0M |
| Adjustments For Decrease Increase In Inventories | -$7.3M | $12.0M |
| Adjustments For Decrease Increase In Other Assets | -$2.6M | -$6.7M |
| Adjustments For Decrease Increase In Trade Account Receivable | -$14.0M | $48.4M |
| Adjustments For Deferred Tax Expense | $6.1M | -$11.3M |
| Adjustments For Depreciation and Amortisation Expense | $18.5M | $20.9M |
| Adjustments For Fair Value Gains Losses | -$2.8M | -$272.0K |
| Adjustments For Finance Costs | $12.0M | $17.6M |
| Adjustments For Gain Loss On Disposal of Investments In Subsidiaries Joint Ventures and Associates | $1.0M | $0 |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | $0 | $8.2M |
| Adjustments For Increase Decrease In Other Liabilities | $421.0K | $4.2M |
| Adjustments For Increase Decrease In Trade Account Payable | $7.1M | -$14.5M |
| Adjustments For Provisions | $256.0K | -$1.6M |
| Adjustments For Sharebased Payments | $17.6M | $6.1M |
| Basic Earnings Loss Per Share From Continuing Operations | $0.52 | $0.22 |
| Basic Earnings Loss Per Share From Discontinued Operations | $0.00 | $-0.01 |
| Cash Flows From Losing Control of Subsidiaries Or Other Businesses Classified As Investing Activities | $873.0K | $0 |
| Comprehensive Income Attributable To Noncontrolling Interests | $492.0K | $140.0K |
| Comprehensive Income Attributable To Owners of Parent | $20.6M | $8.3M |
| Current Accrued Expenses and Other Current Liabilities | $7.7M | $8.4M |
| Current Contract Liabilities | $7.8M | $5.5M |
| Current Prepayments and Other Current Assets | $46.5M | $46.7M |
| Current Tax Assets Current | $9.9M | $9.7M |
| Current Tax Liabilities Current | $10.7M | $13.6M |
| Current Tax Liabilities Noncurrent | $8.9M | $10.5M |
| Current Value Added Tax Payables | $6.2M | $5.9M |
| Deferred Tax Assets | $73.7M | $75.8M |
| Diluted Earnings Loss Per Share From Continuing Operations | $0.51 | $0.21 |
| Diluted Earnings Loss Per Share From Discontinued Operations | $0.00 | $-0.01 |
| Dividends Paid Ordinary Shares Per Share | $0.04 | $0.28 |
| Dividends Recognised As Distributions To Noncontrolling Interests | $0 | $354.0K |
| Equity and Liabilities | $769.5M | $755.3M |
| General and Administrative Expense | $45.2M | $35.2M |
| Impairment Loss Recognised In Profit Or Loss Intangible Assets Other Than Goodwill | $0 | $8.2M |
| Income Tax Relating To Remeasurements of Defined Benefit Plans of Other Comprehensive Income | -$31.0K | -$231.0K |
| Increase Decrease In Cash and Cash Equivalents | $3.9M | $2.7M |
| Increase Decrease Through Sharebased Payment Transactions | $17.9M | $6.2M |
| Interest Paid Classified As Operating Activities | $10.5M | $11.7M |
| Liabilities | $432.1M | $505.9M |
| Noncurrent Derivative Financial Liabilities | $5.4M | $2.5M |
| Noncurrent Recognised Liabilities Defined Benefit Plan | $54.4M | $55.7M |
| Other Adjustments For Noncash Items | -$489.0K | $727.0K |
| Other Comprehensive Income | -$2.8M | -$745.0K |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | -$134.0K | $390.0K |
| Other Inflows Outflows of Cash Classified As Financing Activities | -$508.0K | -$354.0K |
| Other Noncurrent Assets | $4.7M | $5.0M |
| Other Noncurrent Financial Assets | $32.5M | $31.2M |
| Other Noncurrent Liabilities | $1.9M | $3.2M |
| Payments For Debt Issue Costs | $0 | $1.8M |
| Payments For Share Issue Costs | $861.0K | $0 |
| Payments To Acquire Or Redeem Entitys Shares | $8.3M | $2.8M |
| Proceeds From Issuing Shares | $60.0M | $0 |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | $678.0K | $1.7M |
| Profit Loss From Continuing Operations | $23.9M | $9.6M |
| Profit Loss From Discontinued Operations | $0 | -$424.0K |
| Purchase of Treasury Shares | $8.3M | $2.8M |
| Revenue From Rendering of Services | $344.3M | $376.4M |
| Revenue From Sale of Goods | $125.9M | $110.8M |
| Share Issue Related Cost | $59.1M | $0 |
| Share of Profit Loss of Associates Accounted For Using Equity Method | $62.0K | $126.0K |
| Shortterm Employee Benefits Accruals | $21.0M | $26.7M |
| Weighted Average Shares | 0.0M | 0.0M |
Methodology
Every line item above is a fact tagged in Core Laboratories N.V.'s annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (USD), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.